These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22607468)

  • 1. Pyoderma gangrenosum in association with Janus kinase 2 (JAK2V617F) mutation.
    Palanivel JA; Macbeth AE; Levell NJ
    Clin Exp Dermatol; 2013 Jan; 38(1):44-6. PubMed ID: 22607468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idiopathic myelofibrosis and pyoderma gangrenosum involving a mutation of Janus kinase 2 (JAK2V617F), showing poor prognosis.
    Hideki M; Tetsurou T; Sakae F; Kensei K; Makoto O; Toshinobu K
    Eur J Dermatol; 2013 Apr; 23(2):256-7. PubMed ID: 23557850
    [No Abstract]   [Full Text] [Related]  

  • 3. The genetics of pyoderma gangrenosum and implications for treatment: a systematic review.
    DeFilippis EM; Feldman SR; Huang WW
    Br J Dermatol; 2015 Jun; 172(6):1487-1497. PubMed ID: 25350484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
    Liu PC; Caulder E; Li J; Waeltz P; Margulis A; Wynn R; Becker-Pasha M; Li Y; Crowgey E; Hollis G; Haley P; Sparks RB; Combs AP; Rodgers JD; Burn TC; Vaddi K; Fridman JS
    Clin Cancer Res; 2009 Nov; 15(22):6891-900. PubMed ID: 19887489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor.
    Nasifoglu S; Heinrich B; Welzel J
    Br J Dermatol; 2018 Aug; 179(2):504-505. PubMed ID: 29451690
    [No Abstract]   [Full Text] [Related]  

  • 6. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis).
    Marzano AV; Damiani G; Ceccherini I; Berti E; Gattorno M; Cugno M
    Br J Dermatol; 2017 Jun; 176(6):1588-1598. PubMed ID: 27943240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pyoderma gangrenosum with aseptic spleen abscess].
    Brahimi N; Maubec E; Boccara O; Marinho E; Valeyrie-Allanore L; Lecaille C; Sebban V; Hersent B; Picard-Dahan C; Descamps V; Crickx B
    Ann Dermatol Venereol; 2009 Jan; 136(1):46-9. PubMed ID: 19171230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia.
    Puigdecanet E; Espinet B; Lozano JJ; Sumoy L; Bellosillo B; Arenillas L; Alvarez-Larrán A; Solé F; Serrano S; Besses C; Florensa L
    Leukemia; 2008 Jul; 22(7):1368-76. PubMed ID: 18480837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in the PSTPIP1 gene and aberrant splicing variants in patients with pyoderma gangrenosum.
    Nesterovitch AB; Hoffman MD; Simon M; Petukhov PA; Tharp MD; Glant TT
    Clin Exp Dermatol; 2011 Dec; 36(8):889-95. PubMed ID: 21790734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients.
    Binus AM; Qureshi AA; Li VW; Winterfield LS
    Br J Dermatol; 2011 Dec; 165(6):1244-50. PubMed ID: 21824126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome.
    Stichweh DS; Punaro M; Pascual V
    Pediatr Dermatol; 2005; 22(3):262-5. PubMed ID: 15916580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum.
    Shareef MS; Munro LR; Owen RG; Highet AS
    Clin Exp Dermatol; 2012 Mar; 37(2):146-8. PubMed ID: 22103549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pyoderma gangrenosum: case report].
    Cavka V; Situm M; Poduje S; Brtan A; Mandusić N; Cubrilović Z
    Acta Med Croatica; 2012 Oct; 66 Suppl 1():25-8. PubMed ID: 23193817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome.
    Lindor NM; Arsenault TM; Solomon H; Seidman CE; McEvoy MT
    Mayo Clin Proc; 1997 Jul; 72(7):611-5. PubMed ID: 9212761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A sporadic case of pyogenic arthritis, pyoderma gangrenosum and acne syndrome without an identifiable mutation.
    Park BM; Yun SJ; Lee SC; Lee JB
    Clin Exp Dermatol; 2014 Jan; 39(1):73-5. PubMed ID: 23692517
    [No Abstract]   [Full Text] [Related]  

  • 16. Concomitant manifestation of pyoderma gangrenosum and colorectal carcinoma.
    Bunte C; Popp-Habeler J; Mischer P; Tuppy H; Haidenthaler A; Knoflach P; Kirchgatterer A
    Scand J Gastroenterol; 2008; 43(6):756-8. PubMed ID: 18569994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcoidosis and pyoderma gangrenosum: an exceptional association. The role of trauma and immunosuppressive agents.
    Herrero JE; Mascaró JM; Llambrich A; Herrero C
    J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):97-9. PubMed ID: 15649201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyoderma gangrenosum Preceding the diagnosis of systemic lupus erythematosus.
    Waldman MA; Callen JP
    Dermatology; 2005; 210(1):64-7. PubMed ID: 15604550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of JAK2V617F Mutation Prevalence in Patients with Beta Thalassemia Major.
    Tahannejad Asadi Z; Yarahmadi R; Saki N; Jalali MT; Amin Asnafi A; Tangestani R
    Lab Med; 2020 Mar; 51(2):176-180. PubMed ID: 31495895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome): report of a sporadic case without an identifiable mutation in the CD2BP1 gene.
    Hong JB; Su YN; Chiu HC
    J Am Acad Dermatol; 2009 Sep; 61(3):533-5. PubMed ID: 19700023
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.